Depression and coronary heart disease
Abstract
Background: Depressive symptoms are common in coronary heart disease patients, and are associated with increased cardiac risk. Although an important relation exists between depression and coronary heart disease prognosis, the underlying pathophysiological mechanisms are poorly understood. Recent evidences suggest that selective serotonin reuptake inhibitors may improve survival after myocardial infarction in patients with depression.
Conclusions: Recognition, early diagnosis and treatment of this comorbidity may be one of essential factors for the clinical management of coronary artery disease.
Downloads
References
Doris A, Ebneier K, Shajahan P. Depressive illness. Lancet 1999; 354: 1369–75.
Parissis JT, Fountoulaki K, Filippatos G, Adamopoulus S, Paraskevaidis I, Kremastinos D. Depression in coronary artery disease: novel pathophysiological mechanism and therapeutic implications. Int J Cardiol 2006; (Epub ahead of print).
Shimbo D, Davidson KW, Haas DC, Fuster V, Badimon JJ. Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. J Thromb Haemost 2005; 3: 897–5.
Musselman DL, Evans DL, Nemeroff CG. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580–92.
Steptoe A, Whitehead DL. Depression, stress, and coronary heart disease: the need for more complex models. Heart 2005; 91: 419–20.
Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4–11.
Ruo B, Rumsfeld JS, Hlatky MA. Depressive symptoms and health related quality of life: the Heart and Soul Study. JAMA 2003; 290: 215–21.
Frasure-Smith N, Lespérance F, Talajic M. Depression and 18- month prognosis after myocardial infarction. Circulation 1995; 91: 999–1005.
Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819–25.
Grunau GL, Ratner PA, Goldner EM, Sheps S. Is early- and lateonset depression after acute myocardial infarction associated with long-term survival in older adults? A population-based study. Can J Cardiol 2006; 22: 473–8.
Strik JJ, Denollet J, Lousberg R, Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 2003; 42: 1801–7.
Stewart RA, North FM, West TM, Sharples KJ, Simes RJ, Colquhoun DM, et al. Depression and cardiovascular morbidity and mortality: cause or consequence? Eur Heart J 2003; 24: 2027–37.
Van Melle JP, De Jonge P, Ormel J, Crijns HJ, Van Veldhuisen DJ, Honig A, et al. Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J 2005; 22: 2650–6.
Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet 2001; 358: 1766–71.
Kop WJ, Ader DN. Assessment and treatment of depression in coronary artery disease patients. Ital Heart J 2001; 2: 890–94.
Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndrome. Am J Cardiol 2002; 89: 331–3.
Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003; 41 Suppl 4: 7–14.
Schins A, Honig A, Crijns H, Baur L, Hamulyak K. Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as a missing link? Psychosom Med 2003; 65: 729–37.
Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarkers of vascular disease. Circulation 2003; 108: 2054–9.
Broadley AJ, Korszun A, Jones CJ, Freneaux MP. Arterial endothelial function is impaired in treated depression. Heart 2002; 88: 521–3.
Chrapko WE, Yurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004; 56: 129–34.
Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation 2000; 102: 1773–9.
Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005; 95: 317–21.
Panagiotakos DB, Pitsavos C, Chrysohon C, Tsetsekou E, Papageorgiou C, Christodoulou G. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people: the ATTICA study. Eur Heart J 2004; 25: 492–9.
Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004; 29: 1119–28.
Parissis J, Adamopoulos S, Rigas A, Kostakis G, Kalatzas D, Venetsanov K, et al. Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004; 94: 1326–8.
Carney RM, Blumenthal JA, Stein PK, Watkind L, Catellier D, Berkman LF, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024–8.
Frasure-Smith N, Lespérance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995; 14: 388–98.
Denollet J, Brutsaert DL. Personality disease severity, and the risk of long-term cardiac events in patients with decreased ejection fraction after myocardial infarction. Circulation 1998; 97: 167–73.
Swenson JR, O’Connor CM, Barton D, Van Zyl LT, Swedberg K, Forman LM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003; 92: 1271–6.
Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701– 9.
Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman- Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62: 783–9.
Taylor RC, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792–8.
Joynt KE, O’Connor CM. Lessons from SADHART, ENRICHD, and other trials. Psychosom Med 2005; 67 Suppl 1: 63–6.
Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zylt LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events. Circulation 2003; 108: 939–44.
Celada P, Dolera M, Alvarez E, Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25: 243–9.
Helmeste D, Tang S, Reist C, Vu R. Serotonin uptake inhibitors modulate intracellular calcium mobilization in platelets. Eur J Pharmacol 1995; 288: 373–7.
Schins A, Hamuljak K, Scharpe S, Lousberg R, Van Melle J, Crijns H, et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sci 2004; 76: 637–50.
Geer E, Child J, Shimbo D, Maayanis S, Reddy S, Badimon JJ, et al. Comparative effects of paroxetine and nefazodone on human platelet aggregation and vascular reactivity. J Am Coll Cardiol 2000; 35 Suppl A: 266.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
